New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines
|
|
- Reynard Ferguson
- 6 years ago
- Views:
Transcription
1 Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular Disease Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA Summary: The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) guidelines for lipid-lowering therapy to reduce coronary heart disease (CHD) risk contain a number of features that distinguish them from the previous ATP guidelines. These new features include modifications in lipid/lipoprotein levels considered optimal, abnormal, or reflective of risk; increased focus on primary prevention through use of Framingham risk scoring to define risk in persons with multiple lipid/nonlipid risk factors; and increased focus on the association of the metabolic syndrome with CHD risk. The introduction of the category of CHD risk equivalents including persons with atherosclerotic disease, diabetes, or 10-year CHD risk > 20% based on Framingham scoring results in an increase over previous guidelines in the proportion of patients categorized as being at high risk and therefore eligible for more intensive low-density lipoprotein cholesterol (LDL-C)-lowering therapy. Use of the new secondary therapeutic target of non-high-density lipoprotein cholesterol should improve management of lipid risk factors in patients who have elevated triglyceride levels after LDL-C goals have been met. These new features of the NCEP ATP III guidelines should improve identification and treatment of patients with dyslipidemias associated with CHD risk. Key words: statins, low-density lipoprotein cholesterol, hypercholesterolemia, Adult Treatment Panel III Address for reprints: H. Bryan Brewer, Jr, M.D. Chief, Molecular Disease Branch National Heart, Lung, and Blood Institute National Institutes of Health Building 10 - Magnuson CC, Room 7N Center Drive Bethesda, MD 20814, USA bryan@mail.nih.gov. Introduction The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) has provided updated guidelines for the clinical management of patients with dyslipidemia. 1 New features of the guidelines include alterations in categorical definitions of optimal, normal, or elevated lipid/ lipoprotein levels; increased focus on global risk assessment, including introduction of the concept of coronary heart disease (CHD) risk equivalents; increased focus on the metabolic syndrome; and introduction of the new treatment target of nonhigh-density lipoprotein cholesterol (non-hdl-c) in patients with elevated triglycerides. Under the ATP III guidelines, an estimated 36 million U.S. individuals are eligible for cholesterol-lowering therapy a 140% increase over ATP II. 2 Changes in Lipid/Lipoprotein Categories Low-density lipoprotein cholesterol (LDL-C) continues to be the primary target of cholesterol-lowering therapy to reduce CHD risk. Animal experiments, laboratory investigations, epidemiologic studies, and studies of genetic forms of hypercholesterolemia indicate that LDL-C is a major cause of CHD and demonstrate that LDL is the most abundant and best-characterized atherogenic lipoprotein. 1 Numerous clinical trials of lipid-lowering therapy have demonstrated that LDL-C-lowering therapy reduces risk for CHD. 3 8 Thus, as with previous guidelines, the primary goals of lipid-lowering therapy and the cut points for initiating therapy are expressed in terms of LDL- C levels. 1 Other changes in lipid/lipoprotein classification include updated HDL-C and triglyceride classifications. Low-Density Lipoprotein Cholesterol Under the ATP III guidelines, the optimal LDL-C level for all persons is identified as < 100 mg/dl a marked reduction from the desirable level of < 130 mg/dl under ATP II guidelines. The classification of LDL-C levels, as shown in Table I, reflects the recognition that the relation of LDL-C to CHD risk
2 III-20 Clin. Cardiol. Vol. 26 (Suppl. III) April 2003 TABLE I Adult Treatment Panel III classification of low-density lipoprotein cholesterol, total cholesterol, high-density lipoprotein cholesterol, and triglycerides Lipid value is continuous over the range of LDL-C levels. It is important to note that the recent findings from the Heart Protection Study may have a significant impact on LDL-C targets and treatment initiation levels in lipid-lowering therapy. 8 This study, in patients with vascular disease, hypertension, or diabetes, has shown significant CHD event reduction in commonly observed plasma cholesterol concentrations, including among patients initiating therapy at LDL-C levels < 100 mg/dl. High-Density Lipoprotein Cholesterol Classification LDL-C (mg/dl) <100 Optimal Near or above optimal Borderline high High 190 Very high Total cholesterol (mg/dl) < 200 Desirable Borderline high 240 High HDL-C (mg/dl) < 40 Low 60 High Triglycerides (mg/dl) <150 Normal Borderline high High 500 Very high Abbreviations: LDL-C = low-density lipoprotein cholesterol, HDL- C = high-density lipoprotein cholesterol. Low HDL-C is recognized as a strong predictor of CHD, although its strength as an independent predictor continues to be controversial. Although clinical trial evidence suggests that increasing HDL-C reduces risk of CHD, 9 insufficient evidence exists to establish a therapeutic goal for HDL-C. The ATP III guidelines change the definition of categorical low HDL-C as a risk factor from < 35 to < 40 mg/dl to reflect better the risk associated with decreased HDL-C levels. The change was based on a number of considerations, including (1) the fact that the inverse relation of HDL-C and CHD risk is a continuous variable, and risk associated with low HDL-C is clearly evident at levels > 35 mg/dl; (2) the desire to raise awareness of the status of low HDL-C as an indicator of the presence of other risk factors; and (3) the fact that such modifiable risk factors as obesity and inactivity contribute modestly to decreased HDL-C levels. Triglycerides It remains a matter of debate whether elevated triglyceride levels constitute an independent risk factor for CHD. However, increased evidence of an independent association has accumulated since the ATP II guidelines were formulated, 10 and evidence suggests that increased quantities of atherogenic remnant lipoproteins augment CHD risk beyond that predicted by LDL when triglyceride levels are 200 mg/dl. For these reasons, and since detection of elevated triglycerides can help identify patients at risk for CHD via other lipid and nonlipid factors, ATP III has substantially lowered the triglyceride levels defined as normal, borderline high, high, and very high (Table I). 1 Global Risk Assessment Using the Framingham Scoring System The ATP III increases the focus on primary CHD prevention in persons with multiple risk factors, since many exhibit relatively high risk for CHD and would benefit from more intensive LDL-C-lowering treatment than was previously recommended. 1 The guidelines have introduced the concept of CHD risk equivalents, indicating conditions or combinations of risk factors that place patients at future risk of CHD events equivalent to that in patients with established CHD. The category of CHD risk equivalents includes documented atherosclerotic disease other than CHD (including peripheral vascular disease, abdominal aortic aneurysm, and carotid artery disease), diabetes, and a 10-year risk for CHD > 20% based on the Framingham risk scoring system. The inclusion of diabetes as a CHD risk equivalent is based on a substantial body of data indicating that diabetes in persons without CHD is associated with risk of CHD events equivalent to risk for events in those with established CHD. 11, 12 The Framingham scoring system is intended to be used primarily in persons with two or more CHD risk factors. are assigned, added, and subtracted on the basis of age, total cholesterol level, smoking versus nonsmoking, HDL-C level, and systolic blood pressure (Tables IIA and IIB). 1 Point totals correlate with absolute 10-year risk for CHD, with patients being categorized according to whether their risk is > 20%, 10 to 20%, or < 10%; these categories are used to determine recommended intensity of LDL-C-lowering therapy and LDL-C levels at which to initiate therapy (Table III). Persons with a 10- year CHD risk > 20% are in the CHD risk-equivalent category and have the same treatment initiation level and LDL-C target as patients with established CHD or other CHD risk equivalents. This high-risk LDL-C target has been changed from 100 to < 100 mg/dl. Persons with a 10-year risk of 10 to 20% have a lower threshold for initiating drug treatment than those with a lower 10-year risk, with both subcategories having the same treatment target. In ATP III, the category of CHD risk equivalents and the use of a risk-factor scoring system in risk assessment result in an increase in the proportion of patients considered to be at
3 H. B. Brewer, Jr.: NCEP ATP III lipid-lowering guidelines III-21 TABLE IIA Estimate of 10-year risk for men (Framingham point scores) Point total 10-year risk (%) <0 < Age (years) HDL (mg/dl) <40 2 Total Age Age Age Age Age cholesterol (mg/dl) years years years years years < Age Age Age Age Age years years years years years Nonsmoker Smoker Systolic blood pressure (mmhg) If untreated If treated < high risk for CHD and thus having lower LDL-C goals. Using data from the Third National Health and Nutrition Examination Survey (NHANES III), a comparison of ATP II guidelines with those of ATP III reveals a 140% increase in the number of U.S. patients eligible for LDL-C-lowering therapy under ATP III. 2 Metabolic Syndrome The ATP III has increased the focus on metabolic syndrome by defining it as a secondary target of therapy after LDL-C reduction and providing a clinical schema for diagnosis. 1 The presence of metabolic syndrome augments the risk of CHD at any given LDL-C level. A recent report on NHANES III data indicates an age-adjusted prevalence of the metabolic syndrome of 23.7% in the U.S. adult population, with the prevalence increasing from 6.7% in those 20 to 29 years of age to 43.5% in those 60 to 69 years of age, and 42.0% in those 70 years or older. 13 The clinical diagnosis of metabolic syndrome is determined by the presence of at least three risk factors from among abdominal obesity, elevated triglycerides, low HDL-C, elevated blood pressure, and elevated fasting glucose (Table IV). The guidelines recommend that management of patients with metabolic syndrome should focus on reducing underlying causes (e.g., obesity and physical inactivity) and treating associated lipid and nonlipid risk factors. Measures for addressing specific lipid risk factors associated with the metabolic syndrome (i.e., elevated triglycerides and low HDL-C) consist primarily of instituting therapeutic lifestyle changes (TLC) therapy and using non-hdl-c as a target of therapy, as discussed below, after LDL-C goals have been achieved. In patients with metabolic syndrome and very high triglycerides ( 500 mg/dl), triglyceride reduction is the primary focus of initial treatment. In patients with low HDL-C
4 III-22 Clin. Cardiol. Vol. 26 (Suppl. III) April 2003 TABLE IIB Estimate of 10-year risk for women (Framingham point scores) Point total 10-year risk (%) <9 < Age (years) HDL (mg/dl) <40 2 Total Age Age Age Age Age cholesterol (mg/dl) years years years years years < Age Age Age Age Age years years years years years Nonsmoker Smoker Systolic blood pressure (mmhg) If untreated If treated < without elevated triglycerides, specific therapy to increase HDL-C may be considered after LDL-C goals have been achieved and TLC therapy has been applied. Elevated Triglycerides and Non-High-Density Lipoprotein Cholesterol Treatment Targets A challenge routinely faced by clinicians is how to manage patients with hypertriglyceridemia. Currently available data indicate that not all triglycerides are the same in their effects and can thus be considered good or bad triglycerides. This observation is based in part on the finding that hypertriglyceridemia is not always associated with increased CHD risk. 14 Persons who do not appear to be at increased risk for CHD include those with elevated triglycerides in association with familial chylomicronemia syndrome, those who consume large amounts of alcohol, those with estrogen-induced hypertriglyceridemia, and a subset of persons with familial hypertriglyceridemia. However, persons with elevated triglycerides in association with combined hyperlipidemia, diabetes, and metabolic syndrome are at increased risk for CHD. The difference in risk appears to be related to differences in types of lipoprotein particles present in persons with elevated triglycerides. Triglyceride-rich remnant particles appear not to be related to increased CHD risk, whereas cholesterol-rich very-low-density lipoprotein (VLDL) or intermediate-density lipoprotein (IDL) particles are associated with increased risk. In brief, a primary factor in determining the atherogenicity of the cholesterol-rich remnant is the presence of increased concentrations of apolipoprotein (apo)-c-iii on these apo-b-containing lipoproteins. 14 Increased levels of apo-c-iii on apo-bcontaining lipoproteins result in inhibition of lipoprotein lipase, decreasing triglyceride hydrolysis and preventing effective remodeling of triglyceride-rich lipoproteins, and reduce binding of the lipoproteins to LDL and LDL receptor-related receptor proteins; thus, increased apo-c-iii is associated with decreased clearance of triglyceride-rich lipoprotein remnants and accumulation of atherogenic remnants. The formation of small, dense LDL, which is more atherogenic than larger LDL
5 H. B. Brewer, Jr.: NCEP ATP III lipid-lowering guidelines III-23 TABLE III Low-density lipoprotein cholesterol goals and cut points for therapeutic lifestyle changes and drug therapy according to risk category LDL-C level at which LDL-C level at which to Risk category LDL-C goal (mg/dl) to initiate TLC (mg/dl) consider drug therapy (mg/dl) CHD or CHD risk equivalents a < (10-year risk > 20%) ( : drug optional) More than two risk factors < year risk 10 20%: 130 (10-year risk 20%) 10-year risk <10%: 160 Zero or one risk factor b < ( : LDL-C-lowering drug optional) a CHD risk equivalents include other clinical forms of atherosclerosis (e.g., peripheral arterial disease, abdominal aortic aneurysm, symptomatic carotid artery disease), diabetes, and multiple risk factors that confer a 10-year risk of CHD > 20%. b Almost all persons with zero or one risk factor have a 10-year risk < 10%; thus, a 10-year risk assessment in those with zero or one risk factor is unnecessary. Abbreviations: CHD = coronary heart disease, LDL-C = low-density lipoprotein cholesterol, TLC = therapuetic lifestyle changes. particles, is favored by the synthesis of large VLDL particles that exhibit decreased clearance and increased shunting through the plasma delipidation cascade. The resulting triglyceride-rich remnants are good substrates for hepatic lipase, and it is hypothesized that this enzyme plays a key role in formation of the small, dense LDL. The lower levels of HDL-C in patients with elevated triglycerides may also be attributable to increased catabolism of HDL. Thus, elevated triglycerides are associated with increased atherogenic risk when increased levels of cholesterol-rich remnants, a predominance of dense LDL, and reduced HDL-C concentrations are present. To account for the additional risk associated with the increased levels of atherogenic remnant particles, the ATP III guidelines introduce the measurement of non-hdl-c as a TABLE IV Clinical identification of the metabolic syndrome (ATP III): Three or more risk factors Risk factor Abdominal obesity (waist circumference) a Men Women Triglycerides HDL-C Men Women Blood pressure Fasting glucose Defining level > 102 cm (> 40 in) > 88 cm (> 35 in) 150 mg/dl < 40 mg/dl < 50 mg/dl 130/ 85 mmhg 110 mg/dl a Some male patients can develop multiple metabolic risk factors when waist circumference is only marginally increased (e.g., cm, or in). Such patients may have a strong genetic contribution to insulin resistance and should benefit from changes in life habits similar to men with categorical increases in waist circumference. Abbreviations: HDL-C = high-density lipoprotein cholesterol. secondary target of therapy in persons with elevated triglyceride levels. 1 Non-HDL-C is the sum of LDL, VLDL, and IDL cholesterol, and non-hdl-c is the most readily available measure of atherogenic remnant lipoproteins. Measurement of apo-b might also provide a good indicator of atherogenic risk. Apolipoprotein-B is the major apolipoprotein in all atherogenic lipoproteins, and the non-hdl-c measurement includes all apo-b-containing lipoproteins; further, apo-b levels correlate well with LDL-C levels in the setting of normal triglyceride levels and are greatly increased in hypertriglyceridemia. Thus, there is ongoing debate over whether apo-b levels should be used for lipid risk assessment in patients with elevated triglyceride levels, with some data indicating that it may be a better predictor of risk than non- HDL-C in this setting. However, the current recommendations favor use of non-hdl-c, since it has not been clearly demonstrated that use of apo-b levels in risk prediction is superior, and since measurement of non-hdl-c is straightforward and widely available. 15 As shown in Table V, the ATP III non-hdl-c goals are set at 30 mg/dl higher than the LDL-C goals corresponding to each risk category. 1 For patients with elevated triglycerides with or without low HDL-C, these levels serve as targets of treatment after LDL-C goals have been achieved. Apart from using TLC approaches, non-hdl-c goals may be met by intensifying therapy with the LDL-C-lowering drug being used, typically a statin; if further reduction is required, nicotinic acid or a fibrate may be added to statin therapy if appropriate caution is exercised. Conclusion The ATP III guidelines contain a number of new features that reflect continued evolution of our understanding of the relations among lipid risk factors, nonlipid risk factors, and CHD. These include the lowering of the LDL-C level consid-
6 III-24 Clin. Cardiol. Vol. 26 (Suppl. III) April 2003 TABLE V Non-high-density lipoprotein cholesterol goals according to risk category LDL-C goal Non-HDL-C goal Risk category (mg/dl) (mg/dl) CHD and CHD risk equivalents <100 <130 More than two risk factors and 10-year risk 20% <130 <160 Zero or one risk factor <160 <190 Abbreviations: CHD = coronary heart disease, LDL-C = low-density lipoprotein cholesterol, non-hdl-c = non-high-density lipoprotein cholesterol. ered optimal in all individuals to < 100 mg/dl, an increase in the categorical low HDL-C level to < 40 mg/dl to reflect better the risk associated with low HDL-C, and reductions in the levels of triglycerides considered normal or high to focus attention on triglycerides as a risk factor. The introduction of the category of CHD risk equivalents and the use of lipid and nonlipid risk factors to assess CHD risk have resulted in an increased focus on risk in individuals without CHD and will necessitate initiation of more intensive LDL-C-lowering therapy to reach therapeutic targets in many patients. Similarly, the guidelines increase the focus on the association of the metabolic syndrome with CHD risk and on the need to control related lipid and nonlipid risk factors. The introduction of the secondary therapeutic target of non-hdl-c is meant to improve lipid risk reduction in persons with metabolic syndrome and others with elevated triglycerides. It is hoped that the new features of the NCEP ATP III guidelines will provide opportunities to identify and treat more effectively all patients with dyslipidemias associated with increased risk of CHD. References 1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285: (full report available at: gov/guidelines/cholesterol/atp3_rpt.htm). 2. Fedder DO, Koro CE, L Italien GJ: New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: Projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 2002;105: Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344: Sacks FM, Pfeffer MA, Moyé LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335: Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339: Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/ TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J Am Med Assoc 1998;279: Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002;360: Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341: Assmann G, Schulte H, Funke H, Von Eckardstein A: The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998;19(suppl M):M8 M Stamler J, Vaccaro O, Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group: Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: Haffner SM, Lehto S, Rönnemma T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339: Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. J Am Med Assoc 2002;287: Brewer HB Jr: Hypertriglyceridemia: Changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol 1999;83:3F 12F 15. Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C, for the ACCESS Study Group: Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: Effect of 5-hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 2001;88:
MOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationNearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III
... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III Robert L. Talbert, PharmD Abstract Coronary heart disease (CHD) is a common, costly, and undertreated
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationThreshold Level or Not for Low-Density Lipoprotein Cholesterol
... SYMPOSIA PROCEEDINGS... Threshold Level or Not for Low-Density Lipoprotein Cholesterol Based on a debate between Philip J. Barter, MD, PhD, FRACP, and Frank M. Sacks, MD Debate Summary As drugs, such
More informationThe American Diabetes Association estimates
DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular
More informationRECOGNITION OF THE METABOLIC SYNDROME
THE METABOLIC SYNDROME IN CLINICAL PRACTICE Michael H. Davidson, MD* ABSTRACT Patients with the metabolic syndrome remain at significantly elevated risk of morbidity and mortality associated with coronary
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationCoronary heart disease (CHD) has. Clearfield The National Cholesterol Education Program Adult Treatment Panel III guidelines
the osteopathic physician. The treatment approach involves therapeutic lifestyle changes with diet, exercise, and weight loss. It requires regular, careful monitoring of serum cholesterol levels. The new
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationHyperlipidemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes
...PRESENTATIONS... Hyperlipidemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes Based on a presentation by Ronald B. Goldberg, MD Presentation Summary Atherosclerosis accounts for approximately
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationOn May 2001, the Third Adult
THE RISK OF DIABETES: CAN WE IMPACT CHD THROUGH THE ATP III CHOLESTEROL GUIDELINES? * Based on a presentation given by Steven M. Haffner, MD, MPH ABSTRACT Diabetes has been recognized among diabetologists
More informationAlthough medical advances have curbed
PREVENTION OF CORONARY HEART DISEASE IN THE METABOLIC SYNDROME AND DIABETES MELLITUS * Sherita Hill Golden, MD, MHS ABSTRACT The leading cause of death in patients with diabetes is cardiovascular disease.
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationRisk Factors and Primary and Secondary Prevention of Coronary Heart Disease
Special Issue Risk Factors and Primary and Secondary Prevention of Coronary Heart Disease Shung Chull Chae, M.D. Department of Internal Medicine / Division of Cardiology Kyungpook National University College
More informationHDL-C. J Jpn Coll Angiol, 2008, 48: NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart
Online publication March 25, 2009 48 6 2007 2007 HDL-C LDL-C HDL-C J Jpn Coll Angiol, 2008, 48: 463 470 NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart 1987 NIPPON DATA80 Iso 10 MRFIT
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationWhat Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives
9: 1:am Understanding Dyslipidemia Testing and Screening: Importance of Lipoprotein Particle Analysis SPEAKER Matthew Sorrentino, MD, FACC Presenter Disclosure Information The following relationships exist
More informationThe apolipoprotein story
Atherosclerosis Supplements 7 (2006) 23 27 The apolipoprotein story Frank M. Sacks a,b, a Department of Nutrition, Harvard School of Public Health, Boston, MA, USA b Department of Medicine, Harvard Medical
More informationCardiovascular disease (CVD) is the
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Cost Effectiveness of Statin Therapy for the Primary Prevention of Major Coronary Events in Individuals With Type 2 Diabetes
More informationCoronary artery disease remains the leading
UNMET NEEDS IN THE TREATMENT OF ATHEROSCLEROSIS: WHY ARE WE NOT DONE YET? * Evan A. Stein, MD, PhD ABSTRACT Heart disease remains the leading cause of death in the United States. Despite advances in surgical,
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationFibrates. Spotlight on. Fibric acid derivatives (fibrates) have been used. When should I prescribe fibrates? In this article: Andrew s visit
Focus on CME at the University of Alberta Spotlight on By T. K. Lee, MSc (Exp. Medicine), MB, BS, MRCP(UK), ABIM, FRCPC As presented at the Drug Update & Practical Therapeutics Course, November 8, 2002.
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationIt is currently estimated that diabetes prevalence by
clinical Study The Prevalence and Pattern of Dyslipidemia among Type 2 Diabetic Patients at Rural Based Hospital in Gujarat, India Hetal Pandya*, JD Lakhani**, J Dadhania, A Trivedi Abstract Only proper
More informationMetabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD
Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationMedical evidence suggests that
COMBINATION THERAPY TO ACHIEVE LIPID GOALS David G. Robertson, MD* ABSTRACT Coronary heart disease (CHD) remains the leading cause of death in the United States despite recent advances in treatment and
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationComparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients
Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Cardiology Department, Bangkok Metropolitan Medical College and Vajira Hospital, Bangkok, Thailand Abstract
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationThe updated guidelines from the National
BEYOND NCEP ATP III: LESSONS LEARNED AND FUTURE DIRECTIONS * Benjamin J. Ansell, MD, FACP ABSTRACT The National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines provide
More informationKristina Strutt, MBBS; Richard Caplan, PhD*; Howard Hutchison, MD*; Aaron Dane, MSc; James Blasetto, MD* Circ J 2004; 68:
Circ J 2004; 68: 107 113 More Western Hypercholesterolemic Patients Achieve Japan Atherosclerosis Society LDL-C Goals With Rosuvastatin Therapy Than With Atorvastatin, Pravastatin, or Simvastatin Therapy
More informationHypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002
Hypertriglyceridemia Ara Metjian, M.D. Resident s Report 20 December 2002 Review of Lipids Chylomicrons (CM): Dietary lipids absorbed through the GI tract are assembled intracellularly into CM. Very Low
More informationRaising high-density lipoprotein cholesterol: where are we now?
European Heart Journal Supplements (23) 5 (Supplement D), D17 D25 Raising high-density lipoprotein cholesterol: where are we now? Baylor College of Medicine, Houston, Texas, U.S.A. KEYWORDS Apolipoprotein;
More informationMacrovascular Management. What s next beyond standard treatment?
Macrovascular Management What s next beyond standard treatment? Are Lifestyle Modifications Still Relevant in Diabetic Patients? Diet Omega-6 and omega-3 fatty acids have been shown to improve CVD risk
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationPreventing Myocardial Infarction in the Young Adult in the First Place: How Do the National Cholesterol Education Panel III Guidelines Perform?
Journal of the American College of Cardiology Vol. 41, No. 9, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00187-6
More informationTailored Statin Treatment for Type 2 Diabetes. Han, Ki Hoon Asan Medical Center University of Ulsan
Tailored Statin Treatment for Type 2 Diabetes Han, Ki Hoon Asan Medical Center University of Ulsan 1 Cardiovascular disease ; No1. death (2001) respiratory tract infection Other NCD S HIV/AIDS deaths during
More informationChanging lipid-lowering guidelines: whom to treat and how low to go
European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,
More informationATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS
LABORATORY AND RISK FACTORS OF ATHEROSCLEROSIS S R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty RISK FACTORS FOR CHD Clinical Risk Factors Laboratory Risk Factors MAJOR CLINICAL RISK
More informationMetabolic Syndrome: Why Should We Look For It?
021-CardioCase 29/05/06 15:04 Page 21 Metabolic Syndrome: Why Should We Look For It? Dafna Rippel, MD, MHA and Andrew Ignaszewski, MD, FRCPC CardioCase presentation Andy s fatigue Andy, 47, comes to you
More informationThe metabolic syndrome, also called
Metabolic Syndrome/Insulin Resistance Syndrome/Pre-Diabetes O R I G I N A L A R T I C L E Reduction of Cardiovascular Events by Simvastatin in Nondiabetic Coronary Heart Disease Patients With and Without
More informationTHE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS
THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationNCEP Report. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
NCEP Report Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Scott M. Grundy; James I. Cleeman; C. Noel Bairey Merz; H. Bryan Brewer,
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationInfluences of Statins on Glucose Tolerance in Patients with Type 2 Diabetes Mellitus
Original Article 95 Influences of Statins on Glucose Tolerance in Patients with Type 2 Diabetes Mellitus Tatsuro Takano, Tadashi Yamakawa, Mayumi Takahashi, Mari Kimura, and Atsushi Okamura Department
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More informationGuidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease Writing Committee Chair: Paul S. Jellinger,
More informationHyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi
Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More information2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries
Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global
More informationEstablished Risk Factors for Coronary Heart Disease (CHD)
Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland
More informationSince the release of the National Cholesterol PROCEEDINGS FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT
FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT Since the National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines, 3 large
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationZuhier Awan, MD, PhD, FRCPC
Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationCost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T
Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T Record Status This is a critical abstract of an economic evaluation
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationThe importance of both low-density lipoprotein
Improving the Prediction of Cardiovascular Risk: Interaction Between LDL and HDL Cholesterol Steven A. Grover, 1,2,3,4 Marc Dorais, 1,3 and Louis Coupal 1,3 Background. The ratio of total cholesterol to
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationPRIMARY PREVENTION OF ATHEROSCLEROTIC VASCULAR DISEASE
ATHEROSCLEROSIS PRIMARY PREVENTION OF ATHEROSCLEROTIC VASCULAR DISEASE Preventing atherosclerosis before it leads to death and disability should now be possible using lifestyle modification and drugs where
More informationStrategies for the prevention of type 2 diabetes and cardiovascular disease
European Heart Journal Supplements (2005) 7 (Supplement D), D18 D22 doi:10.1093/eurheartj/sui025 Strategies for the prevention of type 2 diabetes and cardiovascular disease Jaakko Tuomilehto 1,2,3 *, Jaana
More informationClinical Investigation and Reports. Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein
Clinical Investigation and Reports Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein Paul M. Ridker, MD; Nader Rifai, PhD; Marc A. Pfeffer, MD; Frank Sacks, MD; Eugene Braunwald,
More informationApplicability of Cholesterol-Lowering Primary Prevention Trials to a General Population
Applicability of Cholesterol-Lowering Primary Prevention Trials to a General Population The Framingham Heart Study ORIGINAL INVESTIGATION Donald M. Lloyd-Jones, MD; Christopher J. O Donnell, MD, MPH; Ralph
More informationnicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck
Scottish Medicines Consortium Resubmission nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck New formulation 6 January 2006 The Scottish Medicines Consortium
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationHigh risk strategies for atherosclerosis
Clinica Chimica Acta 286 (1999) 31 45 High risk strategies for atherosclerosis * Paul Cullen FRCPI, Gerd Assmann FRCP Institute of Clinical Chemistry and Laboratory Medicine and Institute of Arteriosclerosis
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationReducing low-density lipoprotein cholesterol treating to target and meeting new European goals
European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia
More informationThe treatment of coronary heart disease (CHD) The Health Economics of the Treatment of Hyperlipidemia and Hypertension J. McMurray
AJH 1999;12:99S 104S The Health Economics of the Treatment of Hyperlipidemia and Hypertension J. McMurray In the current economic climate it is important to demonstrate that healthcare resources are being
More informationLipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers. New and Old Biomarkers. Disclosures
Lipids, Lipoproteins and Cardiovascular Risk: Getting the Most out of New and Old Biomarkers William Cromwell, MD, FAHA, FNLA Diplomate, American Board of Clinical Lipidology Chief Lipoprotein and Metabolic
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationIMPORTANCE OF HIGH TRIGLYCERIDES AS A CARDIOVASCULAR RISK FACTOR IN INDIAN DIABETIC POPULATION A REVIEW
IMPORTANCE OF HIGH TRIGLYCERIDES AS A CARDIOVASCULAR RISK FACTOR IN INDIAN DIABETIC POPULATION A REVIEW Hiren Pandya Department of Medicine, AMC MET Medical College, Ahmedabad, Gujarat, India Correspondence
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationSafety profile of atorvastatin-treated patients with low LDL-cholesterol levels
Atherosclerosis 149 (2000) 123 129 www.elsevier.com/locate/atherosclerosis Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels Rebecca G. Bakker-Arkema *, James W. Nawrocki,
More informationApolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease. Original Policy Date
MP 2.04.13 Apolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with
More informationPharmaceutical Help to Control Cholesterol
Pharmaceutical Help to Control Cholesterol Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. Clinical Associate Professor, Univ. of Maryland This program has been brought to you by PharmCon
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationHistorically, the term control has been
MANAGEMENT OF DYSLIPIDEMIA: IMPLICATIONS OF THE ADULT TREATMENT PANEL (ATP) III RECOMMENDATIONS James M. McKenney, PharmD 1 ABSTRACT The emphasis in managing dyslipidemia should be given to achieving and
More informationInfluence of Baseline Lipids on Effectiveness of Pravastatin in the CARE Trial
JACC Vol. 33, No. 1 January 1999:125 30 125 Influence of Baseline Lipids on Effectiveness of Pravastatin in the CARE Trial MARC A. PFEFFER, MD, PHD, FACC, FRANK M. SACKS, MD, LEMUEL A. MOYÉ, MD, PHD,*
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationHighlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM
Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More information